Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

1
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Journal Title Analysis
Category Analysis

Results Analysis

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Category

Show more Refine

For: Gauthier J, Turtle CJ. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021. ACTA ACUST UNITED AC 2021;27:98-106. [PMID: 33750068 DOI: 10.1097/ppo.0000000000000508] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]

For:	Gauthier J, Turtle CJ. Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: Current Landscape in 2021. ACTA ACUST UNITED AC 2021;27:98-106. [PMID: 33750068 DOI: 10.1097/ppo.0000000000000508] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]

Number	Cited by Other Article(s)
1	Foster M, Negash Y, Eberhardt L, Bryan WW, Schultz K, Wang X, Xu Y, George B. Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project. MOLECULAR THERAPY - ONCOLYTICS 2022;27:182-194. [DOI: 10.1016/j.omto.2022.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Accepted: 10/18/2022] [Indexed: 11/06/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse

Number

Cited by Other Article(s)

Foster M, Negash Y, Eberhardt L, Bryan WW, Schultz K, Wang X, Xu Y, George B. Cross-study safety analysis of risk factors in CAR T cell clinical trials: An FDA database pilot project. MOLECULAR THERAPY - ONCOLYTICS 2022;27:182-194. [DOI: 10.1016/j.omto.2022.10.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Accepted: 10/18/2022] [Indexed: 11/06/2022]